lilly tirzepatide approval Diabetes drug resolves sleep apnea in up to 52% of patients—is FDA in the cards? F.D.A. Approves New Obesity Drug
Description
The new Eli Lilly pill is orforglipron, an oral GLP-1 medication designed to support weight loss and improve blood sugar

How GLP-1s Could Help the Heart These medications are primarily used to treat conditions, such as diabetes and obesity, both of which are cardiovascular risk factors

If your plan has one: Standard prior authorization for Wegovy will be denied Appeals are usually unsuccessful (exclusions are plan design decisions) Alternative coverage pathways may exist (cardiovascular or sleep apnea indications) If your plan excludes weight loss coverage, Wegovy has a cardiovascular indication and Zepbound has a sleep apnea indication

GLP-1 receptor agonists like Ozempic may actually have anti-inflammatory effects, which could be beneficial for people with conditions like osteoarthritis
Semaglutide is a GLP-1 receptor agonist, which means it helps the body release insulin and controls blood sugar levels
PMID: 16406191
